Finance entity

Galectin Therapeutics, Inc.

Company GALT

Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Faisal Ghiath Sukhtian, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.5.

Last mentioned: 2h ago

RSS updates
Share

Entity pulse

Recent coverage · Galectin Therapeutics, Inc.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Galectin Therapeutics, Inc.

Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Faisal Ghiath Sukhtian, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.5. Source depth averages 2 original sources per story, versus 2.1 across the same-window beat baseline. We currently track 1 Finance story that mention Galectin Therapeutics, Inc., all published on August 16, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 32 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Galectin Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Galectin Therapeutics, Inc. 1

Galectin Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.